The mechanism of ethylene trimerization
and tetramerization with
a chromium–diphosphinoamine (Cr–PNP) catalyst system
has been studied with combined experimental and theoretical methods.
Of the total product output, 1-octene, cyclopentanes, n-alkanes, and higher (C10+) olefins are formed with a
fractional (∼1.4) order response to ethylene concentration,
whereas 1-hexene formation is approximately first-order in ethylene.
Theoretical studies suggest a mechanism involving a cationic monometallic
catalyst in Cr(I) and Cr(III) formal oxidation states. A key feature
of the developed model is the occurrence of a double-coordination
mechanism in which a bis(ethylene) chromacyclopentane intermediate
is responsible for 1-octene formation as well as the other coproducts
that have a greater than first-order response to ethylene. In contrast,
1-hexene is formed primarily from a mono(ethylene) chromacyclopentane
intermediate. The selectivity of catalysis is governed by the competition
between single- and double-coordination pathways. The mechanistic
model developed displays excellent correlation with experimental observations
and is able to fully explain the formation of all products generated
with this catalyst.
The oligomerization of ethylene produces α-olefin distributions ranging from Schulz−Flory distributions to alternating and selective oligomer distributions that can be mathematically analyzed and characterized by recurrence relations.
Linear α-olefins or LAOs are produced by the catalytic oligomerisation of ethylene on a multimillion ton scale annually. A range of LAOs is typically obtained with varying chain lengths which follow a distribution. Depending on the catalyst, various types of distributions have been identified, such as Schulz-Flory, Poisson, alternating and selective oligomerisations such as ethylene trimerisation to 1-hexene and tetramerisation to 1-octene. A comprehensive mathematical analysis for all oligomer distributions is presented, showing the relations between the various distributions and with ethylene polymerisation, as well as providing mechanistic insight into the underlying chemical processes.
The catalytic oligomerization
of ethylene with chromium-based complexes
containing bis(benzimidazolemethyl)amine (BIMA) ligands results in
alternating distributions of linear α-olefins (LAOs). Extremely
high activities are obtained (>100 000 g mmol–1 h–1 bar–1) with N-alkyl-substituted BIMA ligands, whereas bulky groups on the central
nitrogen or alternative central donors result in much lower activities.
Variations in the ligand backbone, as well as methylation of the benzimidazole
units, lead to reduction in activity. The alternating LAO distributions
have been mathematically analyzed using second-order recurrence relations.
The shape of the distributions is affected by ethylene pressure (1–4
bar) and by the cocatalyst to some degree. On the basis of the results
and analysis presented herein, we propose that the alternating behavior
originates from the ability of these chromium BIMA catalysts to undergo
single as well as double ethylene insertion reactions. A minor second
distribution (<5 wt %) of 2-ethyl-1-alkenes is obtained under certain
conditions, resulting from incorporation of 1-butene. DFT studies
(M06L) and experimental observations regarding the reaction between
AlMe3 and the N-methyl BIMA ligand 2 have shown that deprotonation of the benzimidazole N–H
units can occur, which suggests a change in coordination of the BIMA
ligand under oligomerization conditions.
The oligomerisation of ethylene with chromium-based catalysts containing asymmetric BIMA (bis(benzimidazole)methylamine) ligands produces linear alpha olefins (LAOs) that follow an alternating distribution.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.